Expression of the markers BDCA‐2 and BDCA‐4 and production of interferon‐α by plasmacytoid dendritic cells in systemic lupus erythematosus
Open Access
- 11 September 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (9) , 2524-2532
- https://doi.org/10.1002/art.11225
Abstract
Objective To study the expression of blood dendritic cell antigen 2 (BDCA‐2) and BDCA‐4 molecules by plasmacytoid dendritic cells (PDCs) in the blood of patients with systemic lupus erythematosus (SLE), and to study PDC production of interferon‐α (IFNα) and its inhibition by anti–BDCA‐2 and anti–BDCA‐4 antibodies. Methods Peripheral blood mononuclear cells (PBMCs) from SLE patients (SLE PBMCs) and from healthy controls were induced to produce IFNα in vitro by SLE serum containing an endogenous IFNα‐inducing factor (SLE‐IIF) or by herpes simplex virus type 1 (HSV‐1). The frequencies and numbers of BDCA‐2–, BDCA‐3–, and BDCA‐4–expressing cells were analyzed by flow cytometry, and the effects of anti–BDCA‐2 and anti–BDCA‐4 monoclonal antibodies (mAb) on IFNα production were investigated. Results IFNα production by SLE PBMCs induced by SLE‐IIF or HSV‐1 was decreased compared with that of healthy control PBMCs (P = 0.002 and P = 0.0007, respectively). The proportions of BDCA‐2– and BDCA‐3–expressing cells in SLE PBMCs were reduced compared with those in PBMCs from healthy controls (P = 0.01 and P = 0.004, respectively). IFNα producers in culture, especially among SLE PBMCs, displayed reduced BDCA‐2 expression and constituted only a minority of the BDCA‐2–positive cells, at least in healthy control PBMCs (median 18%). IFNα production by both SLE and healthy control PBMCs stimulated by SLE‐IIF or HSV‐1 was markedly reduced by anti–BDCA‐2 mAb (median 81–98% inhibition). Anti–BDCA‐4 mAb only partially inhibited SLE‐IIF–induced IFNα production. Conclusion SLE patients had a reduced number of BDCA‐2–expressing PDCs, also termed natural IFNα‐producing cells, and their IFNα production could be inhibited by anti–BDCA‐2/4 mAb. Such mAb may be a therapeutic option for inhibiting the ongoing IFNα production in SLE patients.Keywords
Funding Information
- Swedish Research Council
- Swedish Rheumatism Foundation
- Swedish Society of Medicine
- 80-Year Foundation of King Gustaf V
- Åke Wiberg Foundation
- Nanna Svartz Foundation
- Magnus Bergvall Foundation
This publication has 47 references indexed in Scilit:
- The natural interferon-α producing cells in systemic lupus erythematosusHuman Immunology, 2002
- Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12European Journal of Immunology, 2001
- Activation of Natural Interferon-α Producing Cells by Apoptotic U937 Cells Combined with Lupus IgG and its Regulation by CytokinesJournal of Autoimmunity, 2001
- Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosusLupus, 2001
- Interferon-α Promotes Survival of Human Primary B-Lymphocytes via Phosphatidylinositol 3-KinaseBiochemical and Biophysical Research Communications, 2001
- Induction of Fas Ligand-Mediated Apoptosis by Interferon-αClinical Immunology, 2000
- Appearance of anti‐DNA antibodies in patients treated with interferon‐αArthritis & Rheumatism, 1993
- lnterleukin-3 Immunoassay in Systemic Lupus Erythematosus Patients: Preliminary DataInternational Archives of Allergy and Immunology, 1993
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumourJournal of Internal Medicine, 1990